We are live on ! Find out more
ABBV icon

AbbVie

1,652 hedge funds and large institutions have $80.2B invested in AbbVie in 2015 Q2 according to their latest regulatory filings, with 123 funds opening new positions, 681 increasing their positions, 636 reducing their positions, and 57 closing their positions.

New
Increased
Maintained
Reduced
Closed

116% more first-time investments, than exits

New positions opened: 123 | Existing positions closed: 57

75% more funds holding in top 10

Funds holding in top 10: 81142 (+61)

23% more capital invested

Capital invested by funds: $65.3B → $80.2B (+$14.9B)

23% more call options, than puts

Call options by funds: $1.49B | Put options by funds: $1.21B

5.39% more ownership

Funds ownership: 69.98%75.37% (+5.4%)

3% more funds holding

Funds holding: 1,6001,652 (+52)

7% more repeat investments, than reductions

Existing positions increased: 681 | Existing positions reduced: 636

Holders
1,652
Holders Change
+52
Holders Change %
+3.25%
% of All Funds
44.5%
Holding in Top 10
142
Holding in Top 10 Change
+61
Holding in Top 10 Change %
+75.31%
% of All Funds
3.83%
New
123
Increased
681
Reduced
636
Closed
57
Calls
$1.49B
Puts
$1.21B
Net Calls
+$274M
Net Calls Change
-$1.84M
Name Holding Trade Value Shares
Change
Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$608M -$51.9M -795,301 -8%
MAA
27
Managed Account Advisors
New Jersey
$567M +$132M +2,024,516 +32%
Invesco
28
Invesco
Georgia
$557M +$44.6M +683,119 +9%
UBS AM
29
UBS AM
Illinois
$529M -$115M -1,755,164 -18%
EIP
30
Epoch Investment Partners
New York
$520M +$102M +1,558,297 +25%
Ameriprise
31
Ameriprise
Minnesota
$492M +$100M +1,533,948 +26%
Legal & General Group
32
Legal & General Group
United Kingdom
$481M +$38.3M +587,045 +9%
UBS Group
33
UBS Group
Switzerland
$468M +$23.7M +363,392 +6%
Goldman Sachs
34
Goldman Sachs
New York
$451M -$124M -1,897,429 -22%
O
35
OrbiMed
New York
$448M +$121M +1,850,100 +38%
CS
36
Credit Suisse
Switzerland
$429M +$89.4M +1,369,226 +27%
BlackRock
37
BlackRock
New York
$398M -$57.8M -884,768 -13%
Deutsche Bank
38
Deutsche Bank
Germany
$393M +$21.1M +322,500 +6%
Franklin Resources
39
Franklin Resources
California
$359M -$43.5M -666,750 -11%
Charles Schwab
40
Charles Schwab
California
$347M +$58.2M +891,070 +21%
PNC Financial Services Group
41
PNC Financial Services Group
Pennsylvania
$334M -$1.66M -25,474 -0.5%
PC
42
PointState Capital
New York
$320M +$40M +612,700 +15%
Fayez Sarofim & Co
43
Fayez Sarofim & Co
Texas
$318M -$13.5M -206,693 -4%
AllianceBernstein
44
AllianceBernstein
Tennessee
$314M +$116M +1,775,713 +61%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$306M +$11.3M +173,513 +4%
Sumitomo Mitsui Trust Group
46
Sumitomo Mitsui Trust Group
Japan
$305M +$19.6M +300,639 +7%
California Public Employees Retirement System
47
California Public Employees Retirement System
California
$303M +$21.6M +330,659 +8%
Westfield Capital Management
48
Westfield Capital Management
Massachusetts
$302M +$18.2M +278,140 +7%
Boston Partners
49
Boston Partners
Massachusetts
$301M -$178M -2,734,032 -38%
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$296M +$91.4M +1,400,241 +47%

ABBV Hedge Fund Activity: Q2 2015 in Review

1,652 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2015, worth a combined $80.2B — up 23% from $65.3B a quarter earlier.

Buyers outnumbered sellers: 123 funds opened new ABBV positions and 57 closed out — a net gain of 66 holders — while 681 added to existing stakes and 636 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $1.95B. The largest seller was Capital Research Global Investors, cutting an estimated $489M.

  • 1,652 institutional investors held AbbVie (ABBV) as of Q2 2015, up from 1,600 in Q1 2015.
  • Funds reported $80.2B of AbbVie stock for Q2 2015, up 23% quarter-over-quarter.
  • 123 funds opened new AbbVie positions in Q2 2015 and 57 closed out, a net change of +66 holders.
  • The largest AbbVie buyer in Q2 2015 was Morgan Stanley, an estimated $1.95B added.
  • The largest AbbVie seller in Q2 2015 was Capital Research Global Investors, an estimated $489M sold.

Based on aggregated 13F filings for Q2 2015.